Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)

Trial Profile

A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanifibranor (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms NATIVE
  • Sponsors Inventiva Pharma

Most Recent Events

  • 22 May 2024 According to Inventiva Pharma media release, data from the study will be presented as poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver (EASL) on June 5-8, 2024 in Milan, Italy.
  • 13 May 2024 According to Inventiva Pharma media release, data from this trial published in the peer-reviewed scientific journal Nature Communications
  • 13 May 2024 Results published in the Inventiva Pharma Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top